<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>건강과 대안 &#187; WHO 위험 과장</title>
	<atom:link href="http://www.chsc.or.kr/tag/WHO%20%EC%9C%84%ED%97%98%20%EA%B3%BC%EC%9E%A5/feed" rel="self" type="application/rss+xml" />
	<link>http://www.chsc.or.kr</link>
	<description>연구공동체</description>
	<lastBuildDate>Mon, 13 Apr 2026 01:34:28 +0000</lastBuildDate>
	<language>ko-KR</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.2</generator>
		<item>
		<title>[돼지독감] WHO, 신종플루 사망자 최소 12220명 집계</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=1610</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=1610#comments</comments>
		<pubDate>Thu, 31 Dec 2009 11:08:45 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[12220명 사망]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[WHO 위험 과장]]></category>
		<category><![CDATA[돌연변이]]></category>
		<category><![CDATA[돼지독감]]></category>
		<category><![CDATA[로슈]]></category>
		<category><![CDATA[신종플루]]></category>
		<category><![CDATA[인플루엔자 대유행]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=1610</guid>
		<description><![CDATA[2009년 12월 30일자 WHO의 2009 H1N1 인플루엔자 대유행(신종플루) 업데이트 81의 원문입니다.전세계적으로 최소한 12220명이 2009 H1N1 인플루엔자로 사망했다고 집계하고 있습니다.&#160;WHO의 마가렛 찬 사무총장은 아직도&#160; 2009 H1N1 인플루엔자 대유행 상태라면서 [...]]]></description>
				<content:encoded><![CDATA[<p><P><FONT size=2>2009년 12월 30일자 WHO의 2009 H1N1 인플루엔자 대유행(신종플루) 업데이트 81의 원문입니다.<BR><BR>전세계적으로 최소한 <FONT face=Verdana>12220명이 <FONT face=Arial>2009 H1N1 인플루엔자로 사망했다고 집계하고 있습니다.&nbsp;</FONT></FONT><BR><BR>WHO의 마가렛 찬 사무총장은 아직도&nbsp;<FONT face=Verdana> </FONT><FONT face=Arial>2009 H1N1 인플루엔자 대유행 상태라면서 신종&nbsp;플루 대유행이 끝나가고 있다는 판단은 아직 이르다고 </FONT><BR>강조하고 있습니다.<BR><BR>마가렛 찬 사무총장은 세계가 신종 돼지독감(돼지 인플루엔자)보다 더 독성이 강하고&nbsp;치명적인 H5N1 조류독감 바이러스에 유발되는 대유행을 피할 수 있기를 바라고 있다고 밝히고 있습니다.<BR><BR>그러나 WHO가 돼지독감 바이러스의 실제 위험성을 지나치게 과장하여 너무나 성급하게 대유행을 선언함으로써 암묵적으로 로슈나 GSK 같은 다국적 거대제약회사의 경제적 이윤을 극대화시켰으며, 에이즈(HIV), 결핵, 말라리아 등의 긴급하게 대처해야 할 질병들에 투입되었으면 더 좋았을 엄청난 자원(인력, 장비, 의약품 등)을 돼지독감 대유행에 허비했다는 비난으로부터 자유롭기는 힘들 것으로 판단됩니다.<BR><BR>=================================================</FONT><FONT size=3>&nbsp;</FONT></P><br />
<H1 class=storyPage>Pandemic (H1N1) 2009 &#8211; update 81</H1><br />
<H3 class=sectionHead2>Weekly update</H3><br />
<P>출처 : WHO, 30 December 2009&nbsp;<BR><A href="http://www.who.int/csr/don/2009_12_30/en/index.html">http://www.who.int/csr/don/2009_12_30/en/index.html</A><BR><BR></SPAN><SPAN>As of 27 December 2009, worldwide more than 208 countries and overseas territories or communities have reported laboratory confirmed cases of pandemic influenza H1N1 2009, including at least 12220 deaths. </SPAN></P><br />
<P><SPAN>WHO is actively monitoring the progress of the pandemic through frequent consultations with the WHO Regional Offices and member states and through monitoring of multiple sources of data. </SPAN></P><br />
<H3 class=sectionHead3>Situation update: </H3><br />
<P><SPAN>The most active areas of pandemic influenza transmission currently are in central and eastern Europe. Focal increases in rates of ILI/ARI during recent weeks were reported in at least three eastern European countries, Georgia, Montenegro, and Ukraine. A high intensity of respiratory diseases activity with concurrent circulation of pandemic influenza persists in parts of southern and eastern Europe, particularly in Greece, Poland, Bulgaria, Serbia, Ukraine, and the Urals Region of the Russian Federation. In Western Europe, influenza transmission remains active and widespread, but overall disease activity has peaked. At least 13 of 21 countries (testing more than 20 sentinel samples) reported that 30% or more of sentinel specimens were positive for influenza, down from a peak of over 70%. All were influenza viruses detected in Western Europe were pandemic H1N1 2009, however, very small numbers of seasonal influenza viruses, making up less than 1% of all influenza viruses detected, were reported in Russia. In addition, limited available data indicates that active, high intensity transmission is occurring in Northern African countries along the Mediterranean coast (Algeria, Tunisia, and Egypt).</SPAN></P><br />
<P><SPAN>In Central Asia, limited data suggest that influenza virus circulation remains active, but transmission may have recently peaked in some places. In West Asia, Israel, Iran, Iraq, Oman, and Afghanistan also appear to have passed their peak period of transmission within the past month, though both areas continue to have some active transmission and levels of respiratory disease activity have not yet returned to baseline levels. </SPAN></P><br />
<P><SPAN>In East Asia, influenza transmission remains active but appears to be declining overall. Influenza/ILI activity continued to decline in Japan, in northern and southern China, Chinese Taipei, and Hong Kong SAR (China). Slight increases in ILI were reported in Mongolia after weeks of declining activity following a large peak of activity over one month ago. In southern Asia, influenza activity continues to be intense, particularly in northern India, Nepal, and, Sri Lanka. Seasonal influenza A (H3N2) viruses are still being detected in very small numbers in China making up about 2.5% of the influenza A viruses detected there.</SPAN></P><br />
<P><SPAN>In North America, influenza transmission remains widespread but has declined substantially in all countries. In the US, sentinel outpatient ILI activity has returned to the seasonal baseline, and indicators of severity, including hospitalizations, paediatric mortality, and P&#038;I mortality have declined substantially since peaking during late October. Rates of hospitalization among cases aged 5-17 years and 18-49 year far exceeded rates observed during recent influenza seasons, while rates of hospitalizations among cases aged >65 years were far lower than those observed during recent influenza seasons. </SPAN></P><br />
<P><SPAN>In the tropical regions of Central and South America and the Caribbean, influenza transmission remains geographically widespread but overall disease activity has been declining or remains unchanged in most parts, except for focal increases in respiratory disease activity in a few countries.<BR><BR>In the temperate regions of the southern hemisphere, sporadic cases of pandemic influenza continued to be reported without evidence of sustained community transmission.</SPAN></P><br />
<P><SPAN>The Global Influenza Surveillance Network (GISN) continues monitoring the global circulation of influenza viruses, including pandemic, seasonal and other influenza viruses infecting, or with the potential to infect, humans including seasonal influenza. For more information on virological surveillance and antiviral resistance please see the weekly virology update (Virological surveillance data, below). </SPAN></P><br />
<P><A href="http://www.who.int/entity/csr/disease/swineflu/laboratory30_12_2009/en/index.html">Weekly update (Virological surveillance data)</A> </P><br />
<P><SPAN>*Countries in temperate regions are defined as those north of the Tropic of Cancer or south of the Tropic of Capricorn, while countries in tropical regions are defined as those between these two latitudes. <BR><BR>**Abbreviations: influenza-like-illness (ILI), acute respiratory infection (ARI), and severe acute respiratory infection (SARI)</SPAN></P><br />
<H3 class=sectionHead2>Qualitative indicators (Week 29 to Week 51: 13 July &#8211; 20 December 2009)</H3><br />
<P><SPAN>The qualitative indicators monitor: the global geographic spread of influenza, trends in acute respiratory diseases, the intensity of respiratory disease activity, and the impact of the pandemic on health-care services. </SPAN></P><br />
<P><A href="http://www.who.int/entity/csr/resources/publications/swineflu/interim_guidance/en/index.html">Human infection with pandemic (H1N1) 2009 virus: updated interim WHO guidance on global surveillance</A><BR>A description of WHO pandemic monitoring and surveillance objectives and methods can be found in the updated interim WHO guidance for the surveillance of human infection with pandemic (H1N1) virus. <BR><BR></P><br />
<P><SPAN>The maps below display information on the qualitative indicators reported. Information is available for approximately 60 countries each week. Implementation of this monitoring system is ongoing and completeness of reporting is expected to increase over time. </SPAN></P><br />
<P><A href="http://www.who.int/entity/csr/resources/publications/influenza/interim_guidance_definitions/en/index.html">List of definitions of qualitative indicators</A> </P><br />
<H3 class=sectionHead3>Geographic spread of influenza activity</H3><br />
<P><A href="http://gamapserver.who.int/h1n1/geographic-spread/h1n1_geographic-spread.html" target=_new>Map timeline</A> </P><br />
<H3 class=sectionHead3>Trend of respiratory diseases activity compared to the previous week</H3><br />
<P><A href="http://gamapserver.who.int/h1n1/trend-resp-diseases/h1n1_trend-resp-diseases.html" target=_new>Map timeline</A> </P><br />
<H3 class=sectionHead3>Intensity of acute respiratory diseases in the population </H3><br />
<P><A href="http://gamapserver.who.int/h1n1/intensity-population/h1n1_intensity-population.html" target=_new>Map timeline</A> </P><br />
<H3 class=sectionHead3>Impact on health care services</H3><br />
<P><A href="http://gamapserver.who.int/h1n1/impact-health/h1n1_impact-health.html" target=_new>Map timeline</A> </P><br />
<H3 class=sectionHead3>Laboratory-confirmed cases of pandemic (H1N1) 2009 as officially reported to WHO by States Parties to the IHR (2005) as of 20 December 2009</H3><br />
<P><A href="http://gamapserver.who.int/h1n1/cases-deaths/h1n1_casesdeaths.html" target=_new>Map of affected countries and deaths</A> </P><br />
<P><SPAN>The countries and overseas territories/communities that have newly reported their first pandemic (H1N1) 2009 confirmed cases since the last web update (No. 80): None. </SPAN></P><br />
<P><SPAN>The countries and overseas territories/communities that have newly reported their first deaths among pandemic (H1N1) 2009 confirmed cases since the last web update (No. 80): Nepal and Armenia. </SPAN></P><br />
<P><SPAN><br />
<TABLE class=MsoNormalTable style="MARGIN-LEFT: 4.65pt; WIDTH: 414.75pt; BORDER-COLLAPSE: collapse; mso-padding-alt: 5.25pt 5.4pt 5.25pt 5.4pt" cellSpacing=0 cellPadding=0 width=553 border=0><br />
<TBODY><br />
<TR style="HEIGHT: 12.75pt; mso-yfti-irow: 0; mso-yfti-firstrow: yes"><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: black 1pt solid; PADDING-LEFT: 5.4pt; BORDER-BOTTOM-WIDTH: 1pt; BORDER-BOTTOM-COLOR: black; PADDING-BOTTOM: 5.25pt; BORDER-LEFT: black 1pt solid; WIDTH: 297.75pt; PADDING-TOP: 5.25pt; HEIGHT: 12.75pt; mso-border-top-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-right-alt: solid black .5pt" vAlign=bottom width=397><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><B><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">Region</SPAN></B><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial"> </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><?XML:NAMESPACE PREFIX = O /><O:P></O:P></SPAN></P></TD><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: black 1pt solid; PADDING-LEFT: 5.4pt; BORDER-LEFT-WIDTH: 1pt; BORDER-LEFT-COLOR: black; PADDING-BOTTOM: 5.25pt; WIDTH: 117pt; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; HEIGHT: 12.75pt; mso-border-top-alt: solid black .5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=156><br />
<P class=MsoNormal style="TEXT-ALIGN: center; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=center><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">Deaths* </SPAN><SPAN style="FONT-SIZE: 8.5pt; BACKGROUND: yellow; COLOR: black; FONT-FAMILY: Verdana; mso-highlight: yellow"><O:P></O:P></SPAN></P></TD></TR><br />
<TR style="HEIGHT: 12.75pt; mso-yfti-irow: 1"><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: black 1pt solid; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; BORDER-LEFT: black 1pt solid; WIDTH: 297.75pt; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; HEIGHT: 12.75pt; mso-border-alt: solid black .5pt" vAlign=bottom width=397><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">&nbsp; </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD><br />
<TD style="BORDER-RIGHT: windowtext 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; WIDTH: 117pt; BORDER-TOP-STYLE: none; PADDING-TOP: 5.25pt; BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT-STYLE: none; HEIGHT: 12.75pt; mso-border-right-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext .5pt" vAlign=bottom noWrap width=156><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">&nbsp; </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD></TR><br />
<TR style="HEIGHT: 25.5pt; mso-yfti-irow: 2"><br />
<TD style="BORDER-TOP-WIDTH: 1pt; BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; BORDER-LEFT: black 1pt solid; WIDTH: 297.75pt; BORDER-TOP-COLOR: black; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; HEIGHT: 25.5pt; mso-border-left-alt: solid black .5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=397><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">WHO Regional Office for <?XML:NAMESPACE PREFIX = ST1 /><ST1:PLACE w:st="on">Africa</ST1:PLACE> (AFRO) </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; WIDTH: 117pt; BORDER-TOP-STYLE: none; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; BORDER-LEFT-STYLE: none; HEIGHT: 25.5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=156><br />
<P class=MsoNormal style="TEXT-ALIGN: center; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=center><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana">130<O:P></O:P></SPAN></P></TD></TR><br />
<TR style="HEIGHT: 25.5pt; mso-yfti-irow: 3"><br />
<TD style="BORDER-TOP-WIDTH: 1pt; BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; BORDER-LEFT: black 1pt solid; WIDTH: 297.75pt; BORDER-TOP-COLOR: black; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; HEIGHT: 25.5pt; mso-border-left-alt: solid black .5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=397><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">WHO Regional Office for the <ST1:COUNTRY-REGION w:st="on"><ST1:PLACE w:st="on">Americas</ST1:PLACE></ST1:COUNTRY-REGION> (AMRO) </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; WIDTH: 117pt; BORDER-TOP-STYLE: none; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; BORDER-LEFT-STYLE: none; HEIGHT: 25.5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=156><br />
<P class=MsoNormal style="TEXT-ALIGN: center; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=center><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana">At least 6670 </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD></TR><br />
<TR style="HEIGHT: 25.5pt; mso-yfti-irow: 4"><br />
<TD style="BORDER-TOP-WIDTH: 1pt; BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; BORDER-LEFT: black 1pt solid; WIDTH: 297.75pt; BORDER-TOP-COLOR: black; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; HEIGHT: 25.5pt; mso-border-left-alt: solid black .5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=397><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">WHO Regional Office for the <ST1:PLACE w:st="on">Eastern Mediterranean</ST1:PLACE> (EMRO) </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; WIDTH: 117pt; BORDER-TOP-STYLE: none; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; BORDER-LEFT-STYLE: none; HEIGHT: 25.5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=156><br />
<P class=MsoNormal style="TEXT-ALIGN: center; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=center><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana">693<O:P></O:P></SPAN></P></TD></TR><br />
<TR style="HEIGHT: 24pt; mso-yfti-irow: 5"><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; BORDER-LEFT: black 1pt solid; WIDTH: 297.75pt; BORDER-TOP-STYLE: none; PADDING-TOP: 5.25pt; HEIGHT: 24pt; BORDER-BOTTOM-STYLE: none; mso-border-left-alt: solid black .5pt; mso-border-right-alt: solid black .5pt" vAlign=bottom width=397><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">WHO Regional Office for <ST1:PLACE w:st="on">Europe</ST1:PLACE> (EURO) </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; WIDTH: 117pt; BORDER-TOP-STYLE: none; PADDING-TOP: 5.25pt; BORDER-LEFT-STYLE: none; HEIGHT: 24pt; BORDER-BOTTOM-STYLE: none; mso-border-right-alt: solid black .5pt" vAlign=bottom width=156><br />
<P class=MsoNormal style="TEXT-ALIGN: center; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=center><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">At least 2422 </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD></TR><br />
<TR style="HEIGHT: 25.5pt; mso-yfti-irow: 6"><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: black 1pt solid; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; BORDER-LEFT: black 1pt solid; WIDTH: 297.75pt; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; HEIGHT: 25.5pt; mso-border-alt: solid black .5pt" vAlign=bottom width=397><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">WHO Regional Office for <ST1:PLACE w:st="on">South-East Asia</ST1:PLACE> (SEARO) </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; BORDER-TOP: black 1pt solid; PADDING-LEFT: 5.4pt; BORDER-LEFT-WIDTH: 1pt; BORDER-LEFT-COLOR: black; PADDING-BOTTOM: 5.25pt; WIDTH: 117pt; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; HEIGHT: 25.5pt; mso-border-top-alt: solid black .5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=156><br />
<P class=MsoNormal style="TEXT-ALIGN: center; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=center><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana">1056<O:P></O:P></SPAN></P></TD></TR><br />
<TR style="HEIGHT: 25.5pt; mso-yfti-irow: 7"><br />
<TD style="BORDER-TOP-WIDTH: 1pt; BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; BORDER-LEFT: black 1pt solid; WIDTH: 297.75pt; BORDER-TOP-COLOR: black; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; HEIGHT: 25.5pt; mso-border-left-alt: solid black .5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=397><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">WHO Regional Office for the Western Pacific (WPRO) </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; WIDTH: 117pt; BORDER-TOP-STYLE: none; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; BORDER-LEFT-STYLE: none; HEIGHT: 25.5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=156><br />
<P class=MsoNormal style="TEXT-ALIGN: center; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=center><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana">1249<O:P></O:P></SPAN></P></TD></TR><br />
<TR style="HEIGHT: 12.75pt; mso-yfti-irow: 8"><br />
<TD style="BORDER-TOP-WIDTH: 1pt; BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; BORDER-LEFT: black 1pt solid; WIDTH: 297.75pt; BORDER-TOP-COLOR: black; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; HEIGHT: 12.75pt; mso-border-left-alt: solid black .5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=397><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">&nbsp; </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; WIDTH: 117pt; BORDER-TOP-STYLE: none; PADDING-TOP: 5.25pt; BORDER-BOTTOM: black 1pt solid; BORDER-LEFT-STYLE: none; HEIGHT: 12.75pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid black .5pt" vAlign=bottom width=156><br />
<P class=MsoNormal style="TEXT-ALIGN: center; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=center><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">&nbsp; </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD></TR><br />
<TR style="HEIGHT: 12.75pt; mso-yfti-irow: 9; mso-yfti-lastrow: yes"><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; BORDER-LEFT: black 1pt solid; WIDTH: 297.75pt; BORDER-TOP-STYLE: none; PADDING-TOP: 5.25pt; BORDER-BOTTOM: windowtext 1pt solid; HEIGHT: 12.75pt; mso-border-left-alt: solid black .5pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid windowtext .5pt" vAlign=bottom width=397><br />
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">Total*</SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"> <O:P></O:P></SPAN></P></TD><br />
<TD style="BORDER-RIGHT: black 1pt solid; PADDING-RIGHT: 5.4pt; PADDING-LEFT: 5.4pt; PADDING-BOTTOM: 5.25pt; WIDTH: 117pt; BORDER-TOP-STYLE: none; PADDING-TOP: 5.25pt; BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT-STYLE: none; HEIGHT: 12.75pt; mso-border-right-alt: solid black .5pt; mso-border-bottom-alt: solid windowtext .5pt" vAlign=bottom width=156><br />
<P class=MsoNormal style="TEXT-ALIGN: center; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=center><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Arial">At least 12220 </SPAN><SPAN style="FONT-SIZE: 8.5pt; COLOR: black; FONT-FAMILY: Verdana"><O:P></O:P></SPAN></P></TD></TR></TBODY></TABLE></SPAN></P><br />
<P><SPAN>* The reported number of fatal cases is an under representation of the actual numbers as many deaths are never tested or recognized as influenza related.</SPAN></P></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=1610/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
